Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) will deliver the opening R&D address at the two-day World Anti-Microbial Resistance (AMR) Congress 2022 taking place in Washington DC on 7-8 September 2022.
World AMR Congress is the world’s largest AMR conference with more than 1,000 attendees from over 50 countries and has been the go-to event globally since 2015 for all stakeholders in the AMR space to meet, brainstorm ideas and formulate initiatives that can combat anti-microbial resistance.
Recce chief scientific officer Michele Dilizia will deliver the opening R&D address titled “Antibiotic Development: What does the Future Hold?”.
Fight against superbugs
There has been a lack of innovation in new antibiotic drug development, with almost every antibiotic on the market based on scientific discoveries from more than 30 years ago – positioning Recce as a sign of new hope in the fight against superbugs on the international stage.
A panel of the World AMR Congress also selected Recce’s Scientific Poster for presentation.
The abstract titled: “RECCE® 327 Demonstrates Bactericidal Activity against Several Microbial Species” is a snapshot of Mechanism of Action (MoA) data gathered by an independent, world-leading antibiotic MoA specialised organisation.
“An urgent global health crisis”
World AMR Congress production director Claire Murphy said that antimicrobial resistance is an urgent global health crisis that requires global attention.
He added: “Innovative drugs and novel strategies are needed now more than ever.
“The World AMR Congress continues to be the most impactful event for the innovative companies, such as Recce, to connect with global AMR stakeholders and further initiatives aimed at combatting this pressing global challenge.”